Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
Hyperinflammatory syndromes comprise a heterogeneous group of disorders characterized by severe inflammation, multiple organ dysfunction, and potentially death. In response to antigenic stimulus (e.g., SARS-CoV-2 infection), overactivated CD8+ T-cells and macrophages produce high levels of proinflam...
Saved in:
Main Authors: | Eduardo Huarte (Author), Michael T. Peel (Author), Katherine Verbist (Author), Brittany L. Fay (Author), Rachel Bassett (Author), Sabrin Albeituni (Author), Kim E. Nichols (Author), Paul A. Smith (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
by: Annalisa Marcuzzi, et al.
Published: (2022) -
Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
by: Paul Smith, et al.
Published: (2021) -
Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis
by: Leland Shapiro, et al.
Published: (2022) -
Weathering a Cytokine Storm
by: Tiffany Y. Shaw MD, et al.
Published: (2016) -
Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
by: Birao Fan, et al.
Published: (2022)